Altamira Therapeutics to Participate in the 4th Annual RAS-Targeted Drug Development Summit
HAMILTON, BERMUDA , Sept. 08, 2022 (GLOBE NEWSWIRE) —
Altamira Therapeutics (“Altamira” or the “Company”) (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it will participate in-person at the 4th Annual RAS-Targeted Drug Development Summit being held on September 26-28, 2022 in Boston, Massachusetts.
Related news for (CYTO)
- Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
- Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
- altamira therapeutics provides update on nasdaq listing
- altamira therapeutics announces extended iso 13485 quality management system certification for bentrio nasal spray
- altamira therapeutics provides business update and first half 2024 financial results